87 related articles for article (PubMed ID: 15009721)
1. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.
Andersen MH; Reker S; Becker JC; thor Straten P
J Invest Dermatol; 2004 Feb; 122(2):392-9. PubMed ID: 15009721
[TBL] [Abstract][Full Text] [Related]
2. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
4. Melanoma inhibitor of apoptosis protein (ML-IAP) specific cytotoxic T lymphocytes cross-react with an epitope from the auto-antigen SS56.
Baek Sørensen R; Faurschou M; Troelsen L; Schrama D; Jacobsen S; Becker JC; Thor Straten P; Andersen MH
J Invest Dermatol; 2009 Aug; 129(8):1992-9. PubMed ID: 19212346
[TBL] [Abstract][Full Text] [Related]
5. Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.
Zhou J; Yuen NK; Zhan Q; Velazquez EF; Murphy GF; Giobbie-Hurder A; Hodi FS
Cancer Immunol Immunother; 2012 May; 61(5):655-65. PubMed ID: 22033581
[TBL] [Abstract][Full Text] [Related]
6. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
7. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
8. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel survivin-derived CTL epitopes.
Reker S; Meier A; Holten-Andersen L; Svane IM; Becker JC; thor Straten P; Andersen MH
Cancer Biol Ther; 2004 Feb; 3(2):173-9. PubMed ID: 14726703
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Andersen MH; Pedersen LO; Capeller B; Bröcker EB; Becker JC; thor Straten P
Cancer Res; 2001 Aug; 61(16):5964-8. PubMed ID: 11507035
[TBL] [Abstract][Full Text] [Related]
11. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
12. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
[TBL] [Abstract][Full Text] [Related]
13. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous immunity against Bcl-xL in cancer patients.
Andersen MH; Reker S; Kvistborg P; Becker JC; thor Straten P
J Immunol; 2005 Aug; 175(4):2709-14. PubMed ID: 16081848
[TBL] [Abstract][Full Text] [Related]
15. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
[TBL] [Abstract][Full Text] [Related]
16. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.
Andersen MH; Pedersen LO; Becker JC; Straten PT
Cancer Res; 2001 Feb; 61(3):869-72. PubMed ID: 11221872
[TBL] [Abstract][Full Text] [Related]
17. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
18. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.
Somasundaram R; Swoboda R; Caputo L; Otvos L; Weber B; Volpe P; van Belle P; Hotz S; Elder DE; Marincola FM; Schuchter L; Guerry D; Czerniecki BJ; Herlyn D
Cancer Res; 2006 Mar; 66(6):3287-93. PubMed ID: 16540682
[TBL] [Abstract][Full Text] [Related]
20. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
